Company Overview

Pliant Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for fibrotic diseases and certain forms of cancer through targeting integrins, which are cell-surface proteins involved in tissue remodeling, fibrosis, and tumor progression. The company operates within the biotechnology and biopharmaceutical industries, with its primary revenue sources historically consisting of collaboration agreements and financing activities rather than commercial product sales, as it has not yet commercialized an approved therapy. Pliant’s lead programs have focused on idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and oncology-related indications involving fibrosis-associated pathways.

The company’s strategy centers on precision-designed small molecule integrin inhibitors intended to selectively block disease-driving mechanisms while limiting off-target effects. Pliant was founded in 2015 and is headquartered in South San Francisco, California. Since its formation, the company has expanded its pipeline through internal discovery efforts and platform-based drug development, advancing multiple candidates into clinical development. Public filings and investor materials identify integrin biology expertise and fibrosis-focused specialization as central competitive differentiators.

Business Operations

Pliant Therapeutics primarily operates as a single biotechnology research and development organization, with activities concentrated in drug discovery, preclinical research, clinical development, regulatory preparation, and corporate partnering. Its pipeline has included programs such as bexotegrast (formerly PLN-74809), an oral dual-selective integrin inhibitor evaluated in pulmonary fibrosis and liver disease, as well as additional integrin-targeted compounds for oncology and fibrotic conditions. The company generates limited operating revenue through strategic collaborations and licensing arrangements while funding operations primarily through equity financing and cash reserves.

Operations are centered in the United States, though the company conducts clinical activities internationally through contract research organizations, clinical trial sites, and development partners. Pliant controls proprietary integrin-focused chemistry and discovery platforms supporting its therapeutic pipeline. Public disclosures have also referenced collaborations with academic institutions and external research organizations to support translational science, biomarker development, and clinical execution. Data regarding any material joint ventures or majority-owned operating subsidiaries remains inconclusive based on available public sources.

Strategic Position & Investments

Pliant Therapeutics’ strategic direction is focused on advancing integrin biology as a therapeutic modality for severe fibrotic diseases with high unmet medical need. The company has prioritized clinical advancement of lead assets targeting pulmonary and hepatic fibrosis while expanding research into oncology applications associated with tumor fibrosis and microenvironment modulation. Its growth initiatives have included progression of mid-stage clinical trials, investment in translational medicine capabilities, and expansion of research programs intended to broaden the applicability of integrin inhibition.

The company has invested heavily in research and development infrastructure and clinical trial execution rather than large-scale acquisitions. Public filings and investor presentations emphasize selective portfolio advancement, disciplined capital allocation, and the development of differentiated oral small molecule therapies. Emerging areas of interest include precision fibrosis therapeutics, biomarker-guided treatment approaches, and integrin-mediated modulation of tissue remodeling pathways. No major transformative acquisitions comparable to large pharmaceutical mergers have been publicly identified in company filings through available reporting periods.

Geographic Footprint

Pliant Therapeutics is headquartered in South San Francisco, California, and its operational footprint is primarily concentrated in the United States. Clinical development activities extend into selected international regions through multicenter trial participation and outsourced development partnerships. The company’s programs have involved clinical sites and regulatory interactions in parts of North America and Europe, particularly for studies related to pulmonary fibrosis and liver disease.

Although Pliant does not maintain the broad commercial infrastructure of a multinational pharmaceutical company, its clinical and scientific activities have international reach through global trial enrollment and collaborations with research institutions. Its investor base and capital market activities are also internationally accessible through its Nasdaq listing under the ticker PLRX.

Leadership & Governance

Pliant Therapeutics was co-founded by executives and scientists with backgrounds in fibrosis biology, medicinal chemistry, and biotechnology company development. The company’s leadership has consistently emphasized science-driven development, disciplined clinical execution, and the pursuit of targeted therapies addressing diseases with limited treatment options. Public statements and corporate materials describe a strategy centered on leveraging integrin expertise to build a focused fibrosis therapeutics platform.

Key executives identified in public filings and company disclosures include:

• Bernard Coulie, M.D., Ph.D. – Chief Executive Officer and Director
• Keith Cummings – Chief Financial Officer
• Eric Lefebvre, M.D. – Chief Medical Officer
• Hans Schambye, M.D., Ph.D. – Chairman of the Board
• Christopher S. Anzalone, Ph.D. – Director
• Peter Ehrenheim – Director

Executive composition and board membership may change over time based on company filings and annual shareholder disclosures.